MicroRNA‐125a attenuates the chemoresistance against ubenimex in non–small cell lung carcinoma via targeting the aminopeptidase N signaling pathway

2019 ◽  
Vol 121 (2) ◽  
pp. 1716-1727
Author(s):  
Chaoyi Li ◽  
Wei Zhai ◽  
Li Wan ◽  
Jingsong Li ◽  
Ai Huang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Aminopeptidase N ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

scholarly journals LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
So-Young Lim ◽  
Iris Macheleidt ◽  
Priya Dalvi ◽  
Stephan C. Schäfer ◽  
Martin Kerick ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Carcinoma Cells ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Integrin Β3 ◽  
Lung Carcinoma Cells

scholarly journals The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma

2018 ◽  
Vol 22 (5) ◽  
pp. 621-629 ◽  
Author(s):  
Dorota Pastuszak-Lewandoska ◽  
Daria Domańska-Senderowska ◽  
Adam Antczak ◽  
Jacek Kordiak ◽  
Paweł Górski ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Expression Levels

Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human non-small cell lung carcinoma A549 cells

Gene ◽  
2018 ◽  
Vol 679 ◽  
pp. 352-359 ◽  
Author(s):  
Venugopal Vinod Prabhu ◽  
Perumal Elangovan ◽  
Sivasithambaram Niranjali Devaraj ◽  
Kunnathur Murugesan Sakthivel
Keyword(s):  
Signaling Pathway ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
A549 Cells ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

scholarly journals Effects of LncRNA MEG3 on immunity and autophagy of non-small cell lung carcinoma through IDO signaling pathway

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chuanqiang Wang ◽  
Xiangbo Tao ◽  
Jungong Wei
Keyword(s):  
Signaling Pathway ◽  
Lung Tissue ◽  
Lung Carcinoma ◽  
Peripheral Blood ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Diagnostic Values ◽  
Nsclc Patients

Abstract Background The study was done to investigate the effect of LncRNA MEG3 on the immunity and autophagy of non-small cell lung carcinoma through the IDO signaling pathway. Methods A total of 78 cases of early NSCLC patients (research group; RG) and 69 cases of health controls (control group; CG) during the same time were included. The contents of LncRNA MEG3 and miR-543 in peripheral blood and tissues and their diagnostic values for NSCLC were detected. The relationship between LncRNA MEG3 and miR-543 and their posttreatment contents and influence on the prognosis of NSCLC patients were tested. The expression of LncRNA MEG3, miR-543, and IDO (IDO1, IDO2, and TDO proteins) in the lung tissue of rats and the immune function in the CG and the RG were detected. The effects of LncRNA MEG3 and miR-543 on the biological behavior of NSCLC cells were determined. The role of LncRNA MEG3, miR-543, and IDO in NSCLC was verified. Results LncRNA MEG3 was low in peripheral blood and tissues, while miR-543 was high (P < 0.05); both had good diagnostic values for NSCLC (P < 0.05). LncRNA MEG3 had a negative correlation with miR-543 (P < 0.05) and influenced the prognosis of NSCLC patients (P < 0.05). LncRNA MEG3 in the lung tissue of rats using IDO inhibitor was elevated compared with that of lung carcinoma model rats (P < 0.05). The level of miR-543 was declined compared with that of lung carcinoma model rats (P < 0.05). The levels of IDO1, IDO2, and TDO proteins were evidently declined compared with those of lung carcinoma model rats (P < 0.05). Compared with lung carcinoma model rats, CD3+, CD4+, and CD4+/CD8+ of IDO inhibitor rats were elevated, while CD8+ was declined (P < 0.05). Cell proliferation and invasion ability and IDO1, IDO2, TDO, Beclin-1, and LC3-II proteins were declined in the sh-LncRNA MEG3 group (P < 0.05), while those in the mimics-miR-543 group were evidently elevated (P < 0.05). However, the double luciferase activity detection and RIP experiment confirmed that there was targeted regulation among them (P < 0.05). Conclusion MEG3 has low expression in NSCLC and affects the immunity and autophagy of NSCLC cells via regulating the miR-543/IDO signaling pathway, which is effective for the treatment of NSCLC.

scholarly journals Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway

2017 ◽  
Vol 44 (2) ◽  
pp. 455-466 ◽  
Author(s):  
Yaoguo Lang ◽  
Xianglong Kong ◽  
Changjun He ◽  
Fengjiao Wang ◽  
Benkun Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Glucose Metabolism ◽  
Signaling Pathway ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Akt Signaling ◽  
Small Cell ◽  
Akt Signaling Pathway ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

Background/Aims: Lung cancer is one of the leading causes for cancer mortality. The poor therapeutic outcome of non-small cell lung carcinoma (NSCLC) is mainly due to late diagnosis and chemoresistance. In this study, we investigated the role of Musashi1 (MSI1) in NSCLC malignancy and chemoresistance. Methods: Colony formation, MTT, glucose uptake and lactate production assays were employed to study lung cancer cell malignancy and chemoresistance. RT-PCR and Western blotting were performed to detect mRNA and protein expressions of genes. We used immunohistochemistry and Pearson correlation analysis to study the relationship of gene expression. Results: We demonstrated that MSI1 was able to promote the proliferation and glucose metabolism of NSCLC cells, and to mediate the sensitivity to chemotherapy drugs in NSCLC cells. Importantly, we found that MSI1 could regulate the activity of Akt signaling. The regulation of NSCLC proliferation, glucose metabolism and chemoresistance by MSI1 was dependent on the modulation of the activity of the Akt signaling pathway. We also found that MSI1 was a target of miR-181a-5p, a microRNA involved in the regulation of cancer development. The expression levels of MSI1 and miR-181a-5p were negatively correlated in NSCLC. Conclusion: MSI1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Akt signaling pathway, which provides a new strategy for the therapy of NSCLC.

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document